Document is current
Any future updates will be listed below
-
Authors
Pollock, Charmaine E.
Sutherland, Heidi G.
Maher, Bridget H.
Lea, Rodney A.
Haupt, Larisa M.
Frith, Alison
Anne MacGregor, E.
Griffiths, Lyn R. https://orcid.org/0000-0002-6774-5475
-
Funding
Funding for this research was provided by:
Merck Company Foundation
Australian Government EIF Super Science Funds
- License Information
-
More Information
Article History
Received: 1 February 2018
Accepted: 6 April 2018
First Online: 18 April 2018
Ethics approval and consent to participate
: The study protocol was approved by Griffith University Human Research Ethics Committee, the Queensland University of Technology Human Ethics Committee (Australia), and the East London and the City Ethics Committee (UK).
: The City of London Migraine Clinic received funding from Merck for clinical trials with telcagepant in migraine. The authors declare that there is no conflict of interest.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
